Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibition of mitochondrial pyruvate carrier 1 by lapatinib ditosylate mitigates Alzheimer's-like disease in D-galactose/ovariectomized rats
Heba M. Mansour, Hala M. Fawzy, Aiman S. El‐Khatib, et al.
Neurochemistry International (2021) Vol. 150, pp. 105178-105178
Closed Access | Times Cited: 23

Showing 23 citing articles:

EGFR is a potential dual molecular target for cancer and Alzheimer’s disease
Hee-Jeong Choi, Yoo Joo Jeong, Ji‐Eun Kim, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 32
Kinases control of regulated cell death revealing druggable targets for Parkinson’s disease
Heba M. Mansour, Ahmed F. Mohamed, Aiman S. El‐Khatib, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101841-101841
Closed Access | Times Cited: 21
Lapatinib ditosylate rescues motor deficits in rotenone-intoxicated rats: Potential repurposing of anti-cancer drug as a disease-modifying agent in Parkinson's disease
Heba M. Mansour, Ahmed F. Mohamed, Mahmoud M. Khattab, et al.
European Journal of Pharmacology (2023) Vol. 954, pp. 175875-175875
Closed Access | Times Cited: 14
Porphyromonas gingivalis-induced periodontitis could contribute to cognitive impairment in Sprague–Dawley rats via the P38 MAPK signaling pathway
Jin Ru, Xiaoqiao Ning, Xiang Liu, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 13
Antineoplastics for treating Alzheimer's disease and dementia: Evidence from preclinical and observational studies
Viswanath Das, John H. Miller, Alladi Charanraj Goud, et al.
Medicinal Research Reviews (2024) Vol. 44, Iss. 5, pp. 2078-2111
Open Access | Times Cited: 5
Exploring Parkinson-associated kinases for CRISPR/Cas9-based gene editing: beyond alpha-synuclein
Heba M. Mansour, Aiman S. El‐Khatib
Ageing Research Reviews (2023) Vol. 92, pp. 102114-102114
Closed Access | Times Cited: 11
Drugs repurposing in the experimental models of Alzheimer’s disease
Sheer A. Joodi, Weam W. Ibrahim, Mahmoud M. Khattab
Inflammopharmacology (2025)
Open Access
Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications
Henry Politte, Lingaiah Maram, Bahaa Elgendy
Biomolecules (2025) Vol. 15, Iss. 2, pp. 223-223
Open Access
FDA-Approved Kinase Inhibitors in Preclinical and Clinical Trials for Neurological Disorders
Austin Lui, Jordan Vanleuven, David Perekopskiy, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1546-1546
Open Access | Times Cited: 16
Inactivation of mitochondrial pyruvate carrier promotes NLRP3 inflammasome activation and gout development via metabolic reprogramming
Lih‐Chyang Chen, Yu‐Jen Chen, Hsin‐An Lin, et al.
Immunology (2023) Vol. 169, Iss. 3, pp. 271-291
Closed Access | Times Cited: 10
Inhibition of the mitochondrial pyruvate carrier in astrocytes reduces amyloid and tau accumulation in the 3xTgAD mouse model of Alzheimer's disease
Kelly Ceyzériat, Aurélien M. Badina, Francesco Petrelli, et al.
Neurobiology of Disease (2024) Vol. 200, pp. 106623-106623
Open Access | Times Cited: 3
The Role of Mitochondrial Pyruvate Carrier in Neurological Disorders
Yue Liu, Xiying Yu, Wei Jiang
Molecular Neurobiology (2024)
Closed Access | Times Cited: 2
The interference between SARS-COV-2 and Alzheimer’s disease: Potential immunological and neurobiological crosstalk from a kinase perspective reveals a delayed pandemic
Heba M. Mansour
Ageing Research Reviews (2024) Vol. 94, pp. 102195-102195
Closed Access | Times Cited: 2
Advancing mitochondrial therapeutics: Synthesis and pharmacological evaluation of pyrazole-based inhibitors targeting the mitochondrial pyruvate carrier
Lingaiah Maram, Jessica M. Michael, Henry Politte, et al.
European Journal of Medicinal Chemistry (2024) Vol. 283, pp. 117150-117150
Open Access | Times Cited: 2
Arsenic Induces GSK3β-Dependent p-Tau, Neuronal Apoptosis, and Cognitive Impairment via an Interdependent Hippocampal ERα and IL-1/IL-1R1 Mechanism in Female Rats
Keerti Gupta, Jitendra Vishwakarma, Asmita Garg, et al.
Toxicological Sciences (2022) Vol. 190, Iss. 1, pp. 79-98
Closed Access | Times Cited: 10
Mitochondrial pyruvate carrier 1 alleviates hypoxic-ischemic brain injury in rats
Yue Liu, Yuan Yuan, Yi Yan, et al.
Life Sciences (2023) Vol. 325, pp. 121686-121686
Closed Access | Times Cited: 6
Repositioning of receptor tyrosine kinase inhibitors
Heba M. Mansour, Aiman S. El‐Khatib
Elsevier eBooks (2023), pp. 353-401
Closed Access | Times Cited: 5
Rutaecarpine Mitigates Cognitive Impairment by Balancing Mitochondrial Function Through Activation of the AMPK/PGC1α Pathway
Min Gong, Jianping Jia
Molecular Neurobiology (2023) Vol. 60, Iss. 11, pp. 6598-6612
Closed Access | Times Cited: 4
Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism in rats: Modulation of dopamine D3 receptor
Heba M. Mansour, Ahmed F. Mohamed, Mahmoud M. Khattab, et al.
Brain Research (2024) Vol. 1834, pp. 148893-148893
Closed Access | Times Cited: 1
Quantification of COX-2 Level in Alzheimer’s Disease Patients to Develop Potential Blood-Based Biomarker for Early Diagnosis and Therapeutic Target
Sakshi Kumari, Priyajit Kaur, Abhinay Kumar Singh, et al.
Journal of Alzheimer s Disease (2024) Vol. 98, Iss. 2, pp. 699-713
Closed Access
Psychopharmacology of Psychiatric Disorders and Food Intake
Samar F. Darwish, Sherif S. Abdel Mageed, Ahmed Amr Raouf, et al.
(2024), pp. 375-396
Closed Access
Nutrition and Psychiatric Disorders: Focus on Schizophrenia
Heba M. Mansour
(2022), pp. 313-368
Closed Access | Times Cited: 2
Sub-anaesthetic doses of Esketamine ameliorate memory impairment in Alzheimer's disease by regulating the BDNF/AKT/mTOR signaling pathway in rats
Chengzhi Wang, Fan Xu, Xinran Yu, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top